A Trial Evaluating Efficacy and Safety of Oxaliplatin With 5-Fluorouracil in Patients With Recurrent Ovarian Carcinoma

NCT01481701CompletedPHASE2INTERVENTIONAL

Summary

Key Facts

Lead Sponsor

Jules Bordet Institute

Enrollment

90

Start Date

2008-10-01

Completion Date

2014-05-01

Study Type

INTERVENTIONAL

Official Title

A Non Randomized Stratified Phase II Trial Evaluating Efficacy and Safety of Oxaliplatin in Combination With 5-Fluorouracil in Patients With Platinum-sensitive and Platinum-resistant Recurrent Ovarian Carcinoma

Interventions

Oxaliplatinoxaliplatin

Conditions

Ovarian CarcinomaRelapse

Eligibility

Age Range

18 Years+

Sex

FEMALE

Inclusion Criteria:

* ovarian carcinoma relapse

Exclusion Criteria:

* neurotoxicity grade III renal clearance \< 60 ml/min

Outcome Measures

Primary Outcomes

Objective response rate

Time frame: at 4 years

Locations

Institut Jules Bordet, Brussels, Belgium